Viridian Therapeutics (VRDN)
(Real Time Quote from BATS)
$17.20 USD
-0.09 (-0.52%)
Updated Jul 30, 2024 12:26 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Viridian Therapeutics, Inc. [VRDN]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
REVEALing Its Plans For SC VRDN-003 --- Pivotals Start August, BLA By 2026
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Are Confident in VRDN-001''s Efficacy, But Being Conservative With the TED Market Size
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Execution Matters -- THRIVE Setting Up For ~September, THRIVE-2 YE24
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TED KOL Check: Untangling The TED Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INVITE: TED KOL Check -- Untangling The TED Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Make Sure To Read Fine Print; Lonigutamab Update/Read Through To VRDN
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Continues to THRIVE --- Awaiting Pivotal Data By Mid-2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kickstart or False Start? What January Tells Us about Biotech Annual Returns
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Target In Sight: New Horizon For VRDN With VRDN-003 Nomination
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The TED Trifecta: Setting the Stage Ahead of SC TED Strategic Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L